Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMIZATION: Insulin Glargine in T2DM
NCT00693771Phase 4Completed
- Sponsor
- Sanofi
- Start
- Apr 2008
- Primary completion
- Jul 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Glycated Hemoglobin A1c at 16 weeks. Started Apr 2008; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00693771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00693771.